Early genomic profiling optimizes treatment selection and expands precision therapy options across thyroid cancer subtypes

Photo by Shubham Dhage / Unsplash

Frontiers in Medicine Published June 6, 2026 Medically reviewed June 6, 2026 DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Consider early genomic profiling to optimize treatment selection and expand precision therapy options in advanced thyroid cancer.

This narrative review examines molecular profiling and targeted therapies for patients with advanced, recurrent, or radioiodine-refractory thyroid cancer. The scope includes various intervention classes such as BRAF/MEK inhibitors, RET/TRK inhibitors, VEGFR-targeted multikinase inhibitors, redifferentiation therapies, PI3K/AKT/mTOR inhibitors, and immune checkpoint inhibitors. The review does not report specific sample sizes or adverse event rates.

The authors synthesize that early and comprehensive genomic profiling, including fusion detection, is essential to optimize treatment selection, address resistance, and expand precision therapy options across disease subtypes. This approach aims to tailor therapies to the specific molecular characteristics of the tumor.

Limitations acknowledged by the authors include the lack of reported data on adverse events, serious adverse events, discontinuations, and tolerability. Additionally, the study phase and setting were not reported. Consequently, the evidence regarding specific efficacy outcomes remains qualitative rather than quantitative.

The practice relevance suggests that clinicians should prioritize genomic profiling early in the management of these patients. However, because safety data were not reported, clinicians must rely on existing literature or clinical experience when considering these targeted agents.

Study Details

Study typeGuideline

EvidenceLevel 5

PublishedJun 2026

View Original Abstract ↓

BackgroundThis review summarizes key actionable molecular alterations in thyroid cancer and examines how molecular profiling can be translated into practical, subtype-specific targeted treatment strategies for advanced, recurrent, or radioiodine-refractory disease.MethodsA narrative synthesis was performed using evidence from landmark clinical trials, current consensus guidelines, and representative translational studies on thyroid cancer drivers and targeted therapies. Molecular targets were categorized by signaling pathways and pathological subtypes (DTC, PTC/FTC, ATC/PDTC, and MTC), with emphasis on clinical indications, efficacy signals, and toxicity profiles.ResultsThe identification of specific genomic drivers, such as BRAF V600E, RET mutations/fusions, and NTRK fusions, has revolutionized the management of thyroid cancer. Precision highlights include the use of BRAF/MEK inhibitors in BRAF-mutant ATC and highly selective RET or TRK inhibitors for fusion-positive tumors. For cases lacking these specific markers, VEGFR-targeted multikinase inhibitors (e.g., lenvatinib) remains the standard of care for RAIR-DTC. Furthermore, “redifferentiation” therapies show promise in restoring radioiodine sensitivity, while emerging pathways like PI3K/AKT/mTOR and immune checkpoints offer new avenues for combination therapy to overcome treatment resistance.ConclusionsThe therapeutic paradigm in thyroid cancer is shifting from non-selective multikinase inhibition toward molecularly matched, combination-based, and adaptively sequenced strategies. Early and comprehensive genomic profiling—including fusion detection—is essential to optimize treatment selection, address resistance, and expand precision therapy options across disease subtypes.